Valproate Sodium Injection shortage
Valproate sodium injections are on the FDA’s drug shortage list as of Nov 21, 2026.
- The companies reporting it blame rising demand.
- 1 other company sells the same medicine and has not reported a problem, so your pharmacy may be able to order another company’s version.
- Status
- FDA term: “Current”
- Products on the record
- 2
- Companies reporting
- 2
- Category
- First posted
- Dec 30, 2020
- Last updated
- Nov 18, 2026
- Medicaid use (2026)
This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD Compiled from public FDA (openFDA) and CMS (Medicaid) data sources. Editorial policy
The Bottom Line
Valproate sodium injection is in a current shortage that has lasted over a year, caused by higher demand. One of the two reporting makers still lists the 500 mg/5 mL strength, and Sagent also lists a 100 mg/mL product that has no reported shortage.
Don’t stop or change your therapy on your own — ask your pharmacist about other companies’ versions (see options) and your prescriber about a long-term plan.
Is Valproate Sodium Still in Shortage? Status as of Nov 21, 2026
Yes, still current as of Nov 21, 2026. Every strength is still made by at least one company. 1 of the 2 companies that reported this shortage says it still has some supply, and 1 other company sells the same medicine and has not reported a problem. Your pharmacy may still need to order it or offer another company’s version.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are listed after them, and the Supply-Risk rating counts them too.
Availability of the Affected Products
From the FDA shortage report: 2 products
Is Every Strength Still Made?
A medicine often comes in several strengths, and more than one company may make each. This shows whether at least one company still makes each strength on the record: a company on the shortage report that still has supply, or another company that sells it.
2 of 2 strengths
- 100 mg/mLStill made by a company
- 500 mg/5 mLStill made by a company
Reporting Companies With Supply
Among the 2 companies that reported this shortage — plus 1 other company listing it, below
1 of 2 reporting
Other Companies Listing the Same Medicine, Not Reporting a Shortage
Companies that list Valproate Sodium Injection with the FDA and have not reported a shortage (not counted in the charts above).
- Sagent Pharmaceuticals
Plus 6 other dosage forms of valproate sodium.
Shortage Timeline
- Nov 18, 2026 Currently in shortage 2 of 2 products affected.
- Oct 14, 2026 FDA refreshed this shortage record 1 product updated.
- Dec 30, 2020 First reported to the FDA 2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Valproate Sodium Products Are Affected, by Company
Only the companies that told the FDA about a supply problem are listed here, so other companies may still have stock (see Where else can I get valproate sodium?).
Company: Fresenius Kabi USA, LLC
-
Valproate Sodium Injection, 100 mg/mL
- Strength
- 100 mg/mL
- Availability
Notes: Next release December 2026. Check wholesalers for inventory.
Reason: Demand increase for the drug
Company: Hikma Pharmaceuticals USA, Inc.
-
Valproate Sodium Injection, 500 mg/5 mL
- Strength
- 500 mg/5 mL
- Availability
Notes: Additional lots will be available. Product will be made available as it is released.
Why Is Valproate Sodium in Shortage?
A note from Dr. Brian Staiger, PharmD · Written Nov 21, 2026
Valproate sodium injection is on the FDA shortage list because of a demand increase. In plain terms, more people need it than the manufacturers expected, so supply hasn't kept up.
This report covers two products. Fresenius Kabi lists its 100 mg/1 mL valproate sodium injection (NDC 63323-494-05) as unavailable right now, and says its next release is December 2026. Hikma lists its 500 mg/5 mL injection (NDC 0143-9785-10) as available, and says more lots will be coming and will be made available as they are released.
I'll be straightforward that the report doesn't give any other cause beyond the higher demand. It also only speaks for these two manufacturers and these specific products, so it doesn't tell us about anyone else's supply.
FDA Reason Codes
What Should I Do If I Take Valproate Sodium?
A note from Dr. Brian Staiger, PharmD · Written Nov 21, 2026
Valproate sodium injection is currently on the FDA drug shortage list, and the overall supply risk is rated low. Every listed strength still has at least one possible source.
Strengths and supply:
- 500 mg/5 mL: Hikma reports this as available, with more lots coming as they are released.
- 100 mg/mL: Fresenius Kabi lists this as unavailable, with its next release expected in December 2026. Another maker, Sagent Pharmaceuticals, has the same medicine in this strength on record.
This shortage has lasted more than a year. The FDA lists the reason as higher demand for the drug. One of the two reporting manufacturers still has supply. This information comes from national, manufacturer-reported data, so it may not match what your local pharmacy or hospital has on hand.
What you can do:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy or care team to order your strength. Pharmacies can check wholesalers and other manufacturers.
- If your usual product is out, your pharmacy may be able to get the same medicine from Sagent, though it may not be in local stock.
- If your product cannot be found, talk with your prescriber or pharmacist about options. A different option may not suit everyone, so it should be chosen by your care team.
- Manufacturer phone numbers are listed on this page for reference. Pharmacies usually handle these calls.
This is general information, not personal medical advice.
Quick checklist for the pharmacy counter
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Where Else Can I Get Valproate Sodium?
From the current FDA NDC Directory: other valproate sodium products from the reporting companies that are not on this shortage record, the same medicine from companies that have not reported a shortage and other dosage forms.
- Some listings are repackagers, which relabel another company’s product.
- A listing is not stock: these may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Other Valproate Sodium Products From the Reporting Companies
The same active ingredient, dosage form and route from the reporting companies, in products that are not on this shortage record.
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Valproate Sodium | 100 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9637-10 |
Same Medicine From Other Companies (Not Reporting a Shortage)
The same active ingredient, dosage form and route, from companies that have not reported a shortage to the FDA.
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Valproate Sodium | 100 mg/mL | Injection, Solution · Intravenous | Sagent Pharmaceuticals | 25021-0797-05 |
Other Dosage Forms of Valproate Sodium
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Solution
- Valproic Acid — VALPROIC ACID 250 mg/5mLPAI Holdings, LLC dba PAI Pharma · Oral
- Valproic Acid — VALPROIC ACID 500 mg/10mLPAI Holdings, LLC dba PAI Pharma · Oral
- Valproic Acid — VALPROIC ACID 250 mg/5mLMajor Pharmaceuticals · Oral
- Valproic Acid — VALPROIC ACID 500 mg/10mLMajor Pharmaceuticals · Oral
- Valproic Acid — VALPROIC ACID 250 mg/5mLAmerican Health Packaging · Oral
- Valproic Acid — VALPROIC ACID 500 mg/10mLAmerican Health Packaging · Oral
Therapeutic Equivalents and Pricing 5 products
Other products the FDA rates as interchangeable with the affected strengths, with what pharmacies pay for each and whether pharmacies are still buying it. Cheapest first.
| Product | Manufacturer | Package | Pharmacy cost per unit (NADAC) | FDA rated equivalent | Availability |
|---|---|---|---|---|---|
| Valproate Sodium 100 mg/mLNDC 00143-9637-10 | Hikma | 10 vials | — | AP | FDA listed |
| Valproate Sodium 500 mg/5mLNDC 00143-9785-10 | Hikma | 10 vials | — | AP | FDA listed |
| Valproate Sodium 100 mg/mLNDC 25021-0797-05 | Sagent | 10 vials | — | AP | FDA listed |
| Valproate Sodium 100 mg/mLNDC 63323-0494-05 | Fresenius | 10 vials | — | AP | FDA listed |
| Valproate Sodium 100 mg/mLNDC 63323-0494-16 | Fresenius | 10 vials | — | AP | FDA listed |
These have the same ingredient, strength, form and route, and the FDA rates them as substitutes (an “AB” rating in its Orange Book). The price is what pharmacies pay on average (CMS’s NADAC survey), not what you pay. Availability comes from recent pharmacy prices, not a stock check.
Other Drugs in the Same Treatment Class
These are different medicines — not other versions of valproate sodium — that fall in the same broad treatment class (anticonvulsants). They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & Classification for pharmacists and billers
- GCN Seq No
- 031533
- GCN
- 64371
- HICL code
- 001882
- Ingredient (HICL)
- Valproic Acid (As Sodium Salt) (Valproate Sodium)
- HIC1 code
- H
- Therapeutic class — broad (HIC1)
- Nervous System (Except Autonomic)
- HIC2 code
- H4
- Therapeutic class — intermediate (HIC2)
- Anticonvulsants
- HIC3 code
- H4B
- Therapeutic class — specific (HIC3)
- Anticonvulsants
- AHFS code
- 28:12.28.00
- AHFS class
- Gaba-Mediated Anticonvulsants
- FDB label name
- VALPROATE SOD 500 MG/5 ML VL
- FDB brand name
- Valproate Sodium
- Legend status
- F — Federal legend — prescription drug or device
- GPI-14
- 72500020102020
- GPI class
- Valproate Sodium
Where does this data come from? Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.
Other Neurology Shortages
- Vigabatrin TabletA company is discontinuing its version · 1 product
- Rivastigmine Extended-Release FilmA company is discontinuing its version · 1 product
- Donepezil Hydrochloride; Memantine Hydrochloride Extended-Release CapsuleA company is discontinuing its version · 2 products
- Lamotrigine Extended-Release TabletA company is discontinuing its version · 6 products
- Tiagabine Hydrochloride TabletA company is discontinuing its version · 4 products
- Frova (Frovatriptan Succinate) TabletA company is discontinuing its version · 1 product
- Benztropine Mesylate InjectionA company is discontinuing its version · 1 product
- Carbatrol (Carbamazepine) Extended-Release CapsuleA company is discontinuing its version · 3 products
Valproate sodium Shortage FAQs
Is valproate sodium still in shortage or on backorder?
Yes — as of Nov 21, 2026 the FDA lists valproate sodium injections as a current shortage (status: “Current”, first reported Dec 30, 2020). The FDA’s record for this shortage covers 2 products from 2 companies. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which strengths of valproate sodium are affected?
The FDA record covers 2 strengths: 100 mg/mL, 500 mg/5 mL. Every strength on the record is still made by at least one company, though stock varies by pharmacy.
Why is valproate sodium on backorder?
The companies reporting it blame rising demand.
Is valproate sodium discontinued?
No. No company on this FDA record has told the FDA it is discontinuing valproate sodium injections. It is listed as a shortage, which is a supply problem, not a medicine being withdrawn.
Which valproate sodium products are affected?
Valproate Sodium Injection, 100 mg/mL (NDC 63323-0494-05); Valproate Sodium Injection, 500 mg/5 mL (NDC 00143-9785-10). The full per-NDC list (availability, company and status) is in the table above — each NDC links to its own page.
When will valproate sodium be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get valproate sodium somewhere?
Another company (Sagent Pharmaceuticals) sells the same medicine and has not reported a problem. 6 other dosage forms of valproate sodium are also listed. See “Where else can I get valproate sodium?” above — stock still varies by pharmacy.
What should I do if I take valproate sodium?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another company or a different strength or package size, and ask your prescriber about a long-term plan before your supply runs out.
How to Read the Supply-Risk Rating
Each drug in shortage gets one point for each of five risk factors that apply to it (listed with its rating). It is our estimate across the country, not a check of your pharmacy’s shelves.
- Low0 to 2 risk factors Your pharmacy can often still get it, though it may need to be ordered.Valproate sodium is rated Low: 2 of 5 risk factors.
- Medium3 risk factors Supply is tight in several ways. Finding it may take some calling around.
- High4 or 5 risk factors, or no company found making it Few companies are left making it, or some strengths have no maker at all. It may be hard to find for a while.
Back to this drug’s rating ↑ · How we rate supply risk, in full
Where This Data Comes From
- The FDA’s drug shortage database, checked every day: the companies, their products and the codes on their boxes (NDCs), the status, the reason and the dates. See the FDA’s record for this shortage ↗
- The FDA’s NDC Directory: the other companies that make the same medicine, which the supply-risk rating counts.
- CMS Medicaid prescription data: how widely it is used. It counts Medicaid prescriptions only, so it is a rough guide, not total U.S. use.
- First Databank and CMS NADAC: matching the same medicine across companies, and what pharmacies pay for the equivalents.
For reference only. Check with your pharmacist, the drug’s maker or the FDA before acting on it.